Reported exposure trends among healthcare personnel COVID-19 cases, USA, March 2020-March 2021

Am J Infect Control. 2022 May;50(5):548-554. doi: 10.1016/j.ajic.2022.01.007. Epub 2022 Apr 14.

Abstract

Background: Health care personnel (HCP) have experienced significant SARS-CoV-2 risk, but exposure settings among HCP COVID-19 cases are poorly characterized.

Methods: We assessed exposure settings among HCP COVID-19 cases in the United States from March 2020 to March 2021 with reported exposures (n = 83,775) using national COVID-19 surveillance data. Exposure setting and reported community incidence temporal trends were described using breakpoint estimation. Among cases identified before initiation of COVID-19 vaccination programs (n = 65,650), we used separate multivariable regression models to estimate adjusted prevalence ratios (aPR) for associations of community incidence with health care and household and/or community exposures.

Results: Health care exposures were the most reported (52.0%), followed by household (30.8%) and community exposures (25.6%). Health care exposures and community COVID-19 incidence showed similar temporal trends. In adjusted analyses, HCP cases were more likely to report health care exposures (aPR = 1.31; 95% CI:1.26-1.36) and less likely to report household and/or community exposures (aPR = 0.73; 95% CI:0.70-0.76) under the highest vs lowest community incidence levels.

Discussion: These findings highlight HCP exposure setting temporal trends and workplace exposure hazards under high community incidence. Findings also underscore the need for robust collection of work-related data in infectious disease surveillance.

Conclusions: Many reported HCP cases experienced occupational COVID-19 exposures, particularly during periods of higher community COVID-19 incidence.

Keywords: Healthcare workers; Public health surveillance; SARS-CoV-2; Workplace exposure.

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / epidemiology
  • Delivery of Health Care
  • Health Personnel
  • Humans
  • SARS-CoV-2
  • United States / epidemiology

Substances

  • COVID-19 Vaccines